Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock Position Lowered by Rafferty Asset Management LLC

Rafferty Asset Management LLC trimmed its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRMFree Report) by 5.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 130,346 shares of the company’s stock after selling 6,859 shares during the period. Rafferty Asset Management LLC owned 0.28% of Mirum Pharmaceuticals worth $3,848,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the company. Arizona State Retirement System purchased a new position in shares of Mirum Pharmaceuticals during the third quarter valued at $222,000. New York State Common Retirement Fund increased its holdings in shares of Mirum Pharmaceuticals by 6.1% in the 3rd quarter. New York State Common Retirement Fund now owns 221,946 shares of the company’s stock valued at $7,013,000 after purchasing an additional 12,694 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Mirum Pharmaceuticals during the third quarter worth approximately $381,000. Swiss National Bank grew its position in Mirum Pharmaceuticals by 1.3% during the third quarter. Swiss National Bank now owns 54,400 shares of the company’s stock valued at $1,719,000 after purchasing an additional 700 shares in the last quarter. Finally, Janney Montgomery Scott LLC grew its position in Mirum Pharmaceuticals by 5.3% during the third quarter. Janney Montgomery Scott LLC now owns 18,925 shares of the company’s stock valued at $598,000 after purchasing an additional 950 shares in the last quarter.

Insider Activity

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt bought 2,000 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The stock was purchased at an average price of $25.80 per share, for a total transaction of $51,600.00. Following the purchase, the chief financial officer now directly owns 12,000 shares in the company, valued at $309,600. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, COO Peter Radovich sold 4,303 shares of the business’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $25.80, for a total transaction of $111,017.40. Following the transaction, the chief operating officer now owns 29,013 shares in the company, valued at approximately $748,535.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Eric Bjerkholt bought 2,000 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, March 18th. The stock was bought at an average price of $25.80 per share, with a total value of $51,600.00. Following the purchase, the chief financial officer now owns 12,000 shares of the company’s stock, valued at approximately $309,600. The disclosure for this purchase can be found here. 22.87% of the stock is currently owned by company insiders.

Mirum Pharmaceuticals Trading Up 0.4 %

NASDAQ:MIRM opened at $25.07 on Friday. The company’s 50 day moving average is $25.03 and its 200-day moving average is $27.50. The company has a quick ratio of 3.47, a current ratio of 3.68 and a debt-to-equity ratio of 1.31. Mirum Pharmaceuticals, Inc. has a 12 month low of $23.14 and a 12 month high of $35.56. The firm has a market cap of $1.18 billion, a price-to-earnings ratio of -6.76 and a beta of 1.10.

Mirum Pharmaceuticals (NASDAQ:MIRMGet Free Report) last announced its earnings results on Wednesday, May 8th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.14). The firm had revenue of $69.22 million during the quarter, compared to the consensus estimate of $69.71 million. Mirum Pharmaceuticals had a negative return on equity of 56.46% and a negative net margin of 69.67%. Equities analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.39 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on MIRM. JMP Securities decreased their target price on shares of Mirum Pharmaceuticals from $72.00 to $66.00 and set a “market outperform” rating for the company in a research note on Thursday, May 9th. SVB Leerink dropped their target price on Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating on the stock in a research report on Monday, March 18th. HC Wainwright reiterated a “buy” rating and set a $58.00 price target on shares of Mirum Pharmaceuticals in a report on Monday, June 3rd. Citigroup increased their price objective on Mirum Pharmaceuticals from $37.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday, May 9th. Finally, Stifel Nicolaus started coverage on shares of Mirum Pharmaceuticals in a research note on Wednesday, April 17th. They issued a “buy” rating and a $48.00 target price for the company. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $49.73.

Check Out Our Latest Stock Report on MIRM

Mirum Pharmaceuticals Profile

(Free Report)

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.

Featured Stories

Institutional Ownership by Quarter for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.